University of Illinois College of Veterinary Medicine
University / teaching hospital
9 current cancer treatment or research opportunities
About Illinois veterinary oncology
Illinois combines its Cancer Care Clinic with a large comparative oncology research group. Its teams study cancer vaccines, immune and cell therapies, radiation combinations and ways to carry treatment directly to a tumor.
Cancer types currently listedHemangiosarcoma, Lymphoma, Oral Melanoma, Osteosarcoma, Soft Tissue Sarcoma, Urothelial Carcinoma
Where visits take placeUniversity of Illinois Veterinary Teaching Hospital, 1008 W Hazelwood Dr, Urbana, IL 61802
Current options at University of Illinois College of Veterinary Medicine
Open an option to see who may qualify, locations, costs or coverage, contact details and the official source.
Radiation plus intratumoral IL-12 immunotherapy for canine osteosarcoma
University of Illinois · USA
Current funded oncology clinical trial
What is being offered: Radiation to the affected limb followed by intratumoral JEN-101 at day 2 and week 2, then amputation at week 4
Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Appendicular location; No metastasis; Planned radiation; Planned amputation
May not qualify if: Prior chemo; Prior local radiation; Prior immunotherapy; Prior steroids; Immunosuppressive
Costs / coverage: Partially funded after eligibility: radiation, JEN-101 and associated treatment-visit charges; follow-up abdominal ultrasound and chest radiographs; and up to $2,500 toward amputation at Illinois are covered. Owner pays screening, recheck exams/bloodwork and remaining amputation cost.
Intravenous Z-007 immune-stimulatory nanoparticle for canine osteosarcoma with pulmonary metastases
University of Illinois · USA
Current funded oncology clinical trial
What is being offered: Up to eight once-weekly intravenous doses of Z-007 with baseline and week-9 CT; compassionate continuation may be offered for objective response
Who may qualify: Confirmed cancer diagnosis required; Metastatic; Measurable lung metastases; chemotherapy washout: 21 days; radiation washout: 7 days
May not qualify if: Immunosuppressive
Costs / coverage: Fully funded after eligibility: trial exams, bloodwork, Z-007 administration and CT scans are covered. Owner pays the initial exam and eligibility diagnostics.
University of Illinois Veterinary Teaching Hospital · USA
Actively recruiting — confirmed on the institution’s current clinical-trials page
What is being offered: One radiation dose followed by four intratumoral IL-12/IL-15 fusion-peptide injections
Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min age years: 1; Min weight kg: 8; Measurable; Planned radiation; Min tumor cm: 1; Max tumor cm: 5
May not qualify if: Prior chemo; Prior local radiation; Prior immunotherapy; Immunosuppressive
Costs / coverage: Fully funded after eligibility. Owner pays the initial consultation and eligibility diagnostics; unrelated-condition costs remain owner-paid.
Surgical treatment study for resectable canine soft tissue sarcoma
University of Illinois Veterinary Teaching Hospital · USA
Actively recruiting — confirmed on the institution’s current clinical-trials page
What is being offered: Tumor biopsy, one intratumoral JEN-101 injection seven days later, then required surgical excision at Illinois seven days after treatment
Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Measurable; Planned surgery; chemotherapy washout: 21 days; Min tumor cm: 1; Max tumor cm: 5
May not qualify if: Prior local radiation; Immunosuppressive
Costs / coverage: Partially funded: cytokine treatment, treatment-day exam, biopsy charges and up to $2,500 toward surgical excision at Illinois are covered. Owner pays initial consultation/eligibility diagnostics and unrelated care.
Intratumoral JEN-101 for recurrent canine soft tissue sarcoma
University of Illinois Veterinary Teaching Hospital · USA
Actively recruiting — confirmed on the institution’s current clinical-trials page
What is being offered: Four intratumoral JEN-101 (IL-12) doses given every two weeks with CT, biopsy and blood monitoring
Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Measurable; Recurrent; Prior surgery; chemotherapy washout: 42 days; radiation washout: 42 days; Min tumor cm exclusive: 2
May not qualify if: Prior immunotherapy; Prior steroids; Immunosuppressive
Costs / coverage: Fully funded after eligibility. Owner pays the initial consultation and eligibility diagnostics; unrelated-condition costs remain owner-paid.
Gilvetmab plus epacadostat for canine bladder urothelial carcinoma
University of Illinois Veterinary Teaching Hospital · USA
Actively recruiting — confirmed on the institution’s current clinical-trials page
What is being offered: Standard palliative piroxicam and gabapentin plus randomization to gilvetmab alone or gilvetmab with oral epacadostat for six months, followed by six months of observation
Who may qualify: Active tumor required; Measurable; Cytology or braf and visible bladder mass
May not qualify if: Prior chemo; Prior local radiation; Prior immunotherapy
Costs / coverage: Fully funded after eligibility, with up to $500 support for protocol-related adverse events treated at Illinois. Owner pays the initial consultation and eligibility diagnostics.
Daunomustine chemotherapy for treatment-naive canine multicentric lymphoma
University of Illinois Veterinary Teaching Hospital · USA
Currently listed as a funded canine lymphoma study by the University of Illinois
What is being offered: Up to five intravenous daunomustine doses every 14 days, with response-guided within-patient dose escalation and examinations/bloodwork seven days after treatment. A single L-asparaginase dose may be added for dogs not in complete remission. Dogs with progressive disease leave the trial and are offered standard care. Long-term visits follow the treatment course. Initial eligibility testing and unrelated care remain owner-paid; participation does not guarantee response.
Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min age years: 1; Min weight kg: 4; Lymphoma response: Newly diagnosed / untreated; Multicentric peripheral node lymphoma
May not qualify if: Prior chemo; Prior steroids; Indolent lymphoma; Small cell lymphoma
Costs / coverage: Study treatment and study visits are fully funded after eligibility is established. Owners pay the initial examination and eligibility diagnostics, unrelated care and uncovered adverse-event costs. The consultation is approximately $250, excluding diagnostics, medication and treatment. Partial adverse-event funding is available for care at Illinois. A $1,000 Illinois hospital credit is provided after completion or removal for stable/progressive disease.
SBRT plus dendritic-cell homing hydrogel for canine appendicular osteosarcoma
University of Illinois Veterinary Teaching Hospital · USA
Currently listed as a funded clinical trial on the Illinois master roster
What is being offered: Three consecutive days of SBRT followed by local dendritic-cell homing hydrogel; weekly follow-up for five weeks
Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Appendicular location; No metastasis; Min age years exclusive: 1; Min weight kg: 5; Planned radiation; Anesthesia candidate; steroid washout days: 14 days
May not qualify if: Prior chemo; Prior local radiation; Prior immunotherapy; Current steroids; Immunosuppressive
Costs / coverage: Fully funded after eligibility: CT, biopsy, three-day SBRT, hydrogel injection, study recheck exams and bloodwork. Owners pay the initial consultation (approximately $250), eligibility diagnostics, pain medication and unrelated care.
FAM-010 chemotherapy for canine splenic hemangiosarcoma — enrolling soon
University of Illinois Veterinary Teaching Hospital · USA
Enrolling soon; study inquiries accepted through the sponsor form. Confirm the next dose-group opening with the study team.
What is being offered: Investigational albumin-linked doxorubicin (FAM-010), given by intravenous infusion every three weeks. Six treatments are planned initially; some dogs may receive up to twelve. All study dogs receive FAM-010; no placebo.
Who may qualify: Splenic primary; Planned doxorubicin; Eligible cohorts: Surgery: Yes; Prior procedure: Splenectomy; Required preferences: Surgery
May not qualify if: Prior chemo; Prior local radiation
Costs / coverage: Familiar covers study screening, FAM-010 treatment and study follow-up care. Owners pay travel to and from Urbana. Coverage of the preceding splenectomy or unrelated care is not specified.
Contact: Use Contact the study team on the official Familiar study page. The form connects eligible inquiries with the Illinois team; confirm when a dose group can start.
Location
University of Illinois Veterinary Teaching Hospital, 1008 W Hazelwood Dr, Urbana, IL 61802
A listing here does not mean every pet will qualify. Enrollment can change, and the study team makes the final decision after reviewing your pet’s diagnosis, records and previous treatment.
Have the pathology report, recent imaging and treatment history ready. Ask whether a referral is required, which visits must happen in person and what the study pays for before making travel plans.
